KADCYLA 160MG INJECTION

KADCYLA 160MG INJECTION can cause peripheral neuropathy, a type of nerve damage that can cause tingling, numbness, or weakness in the hands and feet. If you experience these symptoms during treatment, discuss them with your healthcare provider.

KADCYLA 160MG INJECTION can cause temporary infertility in some patients, particularly women. If fertility preservation is a concern for you, discuss this with your healthcare provider before starting treatment.

KADCYLA 160MG INJECTION is a type of chemotherapy, but it is designed to target HER2-positive cancer cells specifically, which may result in fewer side effects than traditional chemotherapy. Additionally, it is given as a single medication, rather than as a combination of drugs.

KADCYLA 160MG INJECTION may be used in combination with other cancer treatments, such as chemotherapy or targeted therapies. Your healthcare provider can help determine the best treatment plan for you based on your individual needs and medical history.

The use of KADCYLA 160MG INJECTION in patients with active tuberculosis (TB) is not recommended due to the risk of worsening the TB infection. This medication can suppress the immune system, making it harder for the body to fight off infections such as TB. Before starting treatment, your healthcare provider will perform a thorough evaluation of your medical history, including screening for TB.

KADCYLA 160MG INJECTION can cause heart problems, particularly in patients with preexisting heart conditions or risk factors. Your healthcare provider will monitor your heart function closely during the treatment.

KADCYLA 160MG INJECTION may interact with other medicines. It is important to inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal supplements, to avoid potential interactions.

If you are receiving KADCYLA 160MG INJECTION, it's important to be proactive in managing your treatment and monitoring your symptoms. Keep communication with your healthcare provider and report any concerns or side effects as soon as possible. Avoid getting pregnant and breastfeeding during treatment. Use effective birth control during the treatment and at least 7 weeks after the last dose. Immediately contact your healthcare provider in case of any worsening of symptoms or infusion reactions. Take steps to care for yourself physically and emotionally during treatment, and seek support from loved ones and professionals as needed. Maintain a healthy and balanced diet during treatment to support your overall health and well-being. Being informed and engaged in your treatment can help ensure the best possible outcomes and manage potential risks or complications.

KADCYLA 160MG INJECTION is made using the molecule/combination called ADO-TRASTUZUMAB EMTANSINE.

KADCYLA 160MG INJECTION is prescribed for treating certain types of cancer (anti-cancer).

KADCYLA 160MG INJECTION is designed to target specific cancer cells to help treat the disease.